Genius Digital Diagnostics System with the Genius Cervical AI algorithm

by Hologic  · Based in United States → — Empower Your Genius With Ours
Obstetrics & Gynecology Oncology Pathology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

The Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm by Hologic is a groundbreaking in vitro diagnostic device designed to revolutionize cervical cancer screening. It is the first and only FDA-cleared digital cytology system that integrates a new, deep learning-based artificial intelligence (AI) algorithm with advanced volumetric imaging technology.

The system works by converting traditional ThinPrep® Pap test glass slides into high-resolution digital images using the Genius™ Digital Imager. This advanced imager captures multiple layers of the cell spot, merging them into a single, exceptionally clear composite image.

The Genius™ Cervical AI algorithm then rapidly analyzes these digital images, conducting object location and analysis, and classifying the features of each cell and infectious organism. It identifies the most clinically relevant objects and presents them in an AI-generated gallery view on the Genius™ Review Station for review by cytotechnologists and pathologists. This process streamlines cancer screening, enhances disease detection, and can significantly reduce review time per case.

Beyond cervical cancer screening, the system can also be used with ThinPrep® non-gynecological and ThinPrep® UroCyte® microscope slides to aid pathologists in reviewing and interpreting digital images. In regions with CE marking, the system has expanded capabilities to image and review both cell and tissue specimens, allowing for unified digital pathology workflows.

The complete system includes the Genius™ Digital Imager, the Genius™ Image Management Server (IMS) for secure storage and management of digital images and associated data, and the Genius™ Review Station, which supports both local and remote case review, fostering collaboration among geographically dispersed experts.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Deep learning-based AI algorithm for cervical cancer screening
  • Advanced volumetric imaging technology for exceptional image clarity
  • Geniusu2122 Digital Imager for high-resolution whole slide imaging of ThinPrepu00ae Pap test slides
  • Geniusu2122 Image Management Server (IMS) for secure digital image storage and management
  • Geniusu2122 Review Station for local or remote case review and interpretation
  • AI-generated gallery of the most diagnostically relevant cells for efficient review
  • Increased sensitivity for detecting HSIL+, LSIL+, and ASC-H+ lesions compared to manual review
  • Potential for up to 50% reduction in review time per case
  • Identification of infectious organisms and glandular components
  • Supports unified digital workflows for cell and tissue specimens (CE marked in Europe)

Use Cases

  • Assisting in cervical cancer screening and diagnosis
  • Identification of atypical cells, cervical neoplasia, precursor lesions, and carcinoma
  • Review of ThinPrep non-gynecological and UroCyte microscope slide digital images
  • Enhancing laboratory workflow efficiency and optimizing resources
  • Enabling remote case review and collaboration among pathologists/cytologists
  • Aiding in the diagnosis of various cancers and diseases (expanded CE mark in Europe for cell and tissue specimens)

What Physicians Need to Know

Cervical Screening AI
The Genius Cervical AI algorithm is a deep learning-based artificial intelligence designed to assist in cervical cancer screening of ThinPrep Pap test slides. It identifies atypical cells, precancerous lesions (Low Grade Squamous Intraepithelial Lesions, High Grade Squamous Intraepithelial Lesions), and carcinoma.
Enhanced Detection & Sensitivity
The system has demonstrated increased sensitivity for detecting HSIL+ (High-Grade Squamous Intraepithelial Lesions or worse) compared to both manual review and the ThinPrep Imaging System. It also shows increased detection of endocervical components and infectious organisms.
Digital Workflow & Image Analysis
It converts ThinPrep Pap test glass slides into high-resolution, whole-slide digital images using advanced volumetric imaging technology. The AI algorithm then analyzes these images to identify and present a curated gallery of the most clinically relevant objects to cytologists or pathologists for review.
Improved Laboratory Efficiency
The system is designed to enhance laboratory workflows, accelerate review times, and optimize resources by focusing expert attention on the most critical areas of a slide. It enables efficient case review and potential for remote collaboration.
FDA Cleared
The Genius Digital Diagnostics System, when used with the Genius Cervical AI algorithm, is the first and only FDA-cleared digital cytology system for cervical cancer screening.
Physician Tip

Physicians should recognize that the Genius Cervical AI algorithm serves as an advanced aid in cervical cancer screening, enhancing the ability to detect atypical cells and precancerous lesions. It is crucial to remember that the AI complements, rather than replaces, expert cytologist and pathologist review. Leveraging the digital workflow can improve efficiency and facilitate remote consultation for complex cases, potentially leading to faster turnaround times and improved patient outcomes. While the system offers enhanced detection, final diagnostic interpretation remains the responsibility of a qualified pathologist.

The Genius Digital Diagnostics System is an integrated platform comprising the Genius Digital Imager, Genius Image Management Server (IMS), and Genius Review Station. The Genius Cervical AI algorithm operates as a core component within this system. It is specifically indicated for use with ThinPrep Pap test slides prepared using Hologic's ThinPrep 2000, ThinPrep 5000, or ThinPrep Genesis processors and stained with ThinPrep stain. The system supports seamless digital image management and collaboration across laboratory networks.

Details

Category OB/GYN AI, Oncology AI, Pathology AI
Pricing Unknown — Pricing is not publicly disclosed for this medical device. Contact Hologic for a quote.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Cleared AI-estimated

The Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm received FDA clearance on January 31, 2024, under De Novo number DEN210035. It is classified as a Class II device (digital cervical cytology slide imaging system with artificial intelligence algorithm) and is the first and only FDA-cleared digital cytology system combining AI with volumetric imaging for cervical cancer screening.
Integrations
EHR Not specified
Specialties Obstetrics & Gynecology, Oncology, Pathology

What the Web Says

The Hologic Genius Digital Diagnostics System with the Genius Cervical AI algorithm is the first and only FDA-cleared digital cytology system that uses deep-learning AI and volumetric imaging to help identify pre-cancerous lesions and cervical cancer cells. It aims to enhance the review of ThinPrep Pap slides by cytologists and pathologists, improving sensitivity in detecting high-grade lesions and overall efficiency. The system is already available in Europe, Australia, and New Zealand, with commercial availability in the US expected in early 2024.

Overall: Positive

Strengths

  • Increased sensitivity for detecting high-grade squamous intraepithelial lesions (HSIL+) and cervical intraepithelial neoplasia 2 and above (CIN2+).
  • Reduced false negatives for high-grade lesions compared to microscopic review.
  • Improved workload balancing and efficiency for cytologists and pathologists, allowing for more cases to be reviewed per day.
  • Facilitates remote review and collaboration among geographically dispersed experts.
  • Maintains current collection methods and CPT coding, without adding cost for patients.
  • Provides high-resolution digital images and an AI-generated gallery of clinically relevant cells for focused review.

Limitations

  • The technology enhances expert review but does not replace it.
  • Only Hologic ThinPrep slides can be imaged on the Genius platform.
  • Potential need for new CPT codes for AI-assisted platforms, which could impact reimbursement.
  • While sensitivity for HSIL was high in one study, the number of HSIL cases was small, suggesting a need for additional studies.
  • If there is uncertainty in the diagnosis after digital review, direct examination of the glass slide by light microscopy should still be performed.

Based on reviews from: Clinical Pathology Laboratories (CPL), Today's Clinical Lab, ResearchGate, Clinical Lab Products, Hologic, Medical Device Network, Select Science, Acta Cytologica

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Genius Digital Diagnostics System with the Genius Cervical AI algorithm

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

BioSpace
Hologic Announces First and Only FDA-Cleared Digital Cytology System u2013 Geniusu2122 Digital Diagnostics System
Hologic's Geniusu2122 Digital Diagnostics System with the Geniusu2122 Cervical AI algorithm received FDA clearance, making it the first and only FDA-cleared digital cytology system to combine deep-learning AI with volumetric imaging for identifying pre-cancerous lesions and cervical cancer cells.
2024-02
Medical Device Network
FDA grants clearance for Hologic's cancer screening system
The FDA has cleared Hologic's Genius Digital Diagnostics System with the Genius Cervical AI algorithm for cervical cancer screening, a system that digitizes glass slides and applies an AI algorithm to identify pre-cancerous lesions and cervical cancer cells.
2024-02
Select Science
Hologic announces first and only FDA-cleared digital cytology system u2013 Geniusu2122 Digital Diagnostics System
Hologic's Geniusu2122 Digital Diagnostics System, featuring the Geniusu2122 Cervical AI algorithm, has received FDA clearance, becoming the first and only FDA-cleared digital cytology system to use deep-learning AI and advanced volumetric imaging for cervical cancer screening.
2024-02
CAP TODAY
FDA clears Hologic Genius digital cytology system
Hologic's Genius Digital Diagnostics system with the Genius Cervical AI algorithm has gained FDA clearance, marking it as the first FDA-cleared digital cytology system that integrates deep-learning AI with volumetric imaging to detect precancerous lesions and cervical cancer cells.
2024-02
Today's Clinical Lab
First and Only FDA-Cleared Digital Cytology System
Hologic's Geniusu2122 Digital Diagnostics System with the Geniusu2122 Cervical AI algorithm has been cleared by the FDA, making it the first and only digital cytology system to combine AI and advanced volumetric imaging for identifying pre-cancerous lesions and cervical cancer cells.
2024-02
Sonic Healthcare USA (Clinical Pathology Laboratories)
Geniusu2122 Digital Diagnostics System for ThinPrepu00ae Pap Test Review
Clinical Pathology Laboratories (CPL) will adopt Hologic's FDA-cleared Geniusu2122 Digital Diagnostics System, which uses AI-enhanced digital review for ThinPrepu00ae Pap slides, replacing their previous imaging system by December 2025.
2025-12
Medical Product Outsourcing
FDA Approves Hologic's Aptima HPV Assay Primary Screening Option
Hologic's Aptima HPV Assay received expanded FDA approval for primary screening, complementing the earlier clearance of the Genius Digital Diagnostics System with the Genius Cervical AI Algorithm for detecting cytologic abnormalities and precancerous lesions.
2026-02
Frontiers in Medicine
Translational AI in whole-slide image cancer histopathology: state of the art and regulatory-approved solutions
This peer-reviewed article discusses the state of the art in AI for whole-slide image cancer histopathology, referencing the FDA 510(k) summary for Hologic's Genius Digital Diagnostics System with the Genius Cervical AI algorithm as a regulatory-approved solution.
2026-01

Videos

Product demos, reviews, and walkthroughs for Genius Digital Diagnostics System with the Genius Cervical AI algorithm.

View all on YouTube

Frequently Asked Questions

The Geniusu2122 Digital Diagnostics System with the Geniusu2122 Cervical AI algorithm received FDA clearance in February 2024, making it the first and only FDA-cleared digital cytology system for cervical cancer screening in the U.S.. It also holds CE marking for diagnostic use in Europe since November 2021. The system adheres to stringent data privacy and security standards, including HIPAA, to protect patient information through its secure Image Management Server.
The system integrates by digitizing ThinPrep Pap test slides using a Digital Imager, then the AI algorithm identifies and presents 'objects of interest' (OOIs) in a gallery format on a Review Station for pathologist and cytologist review. This aims to streamline workflows, reduce manual workload, and allow professionals to focus on areas flagged by the AI. Users are required to undergo specific training for the device's proper operation.
The Geniusu2122 Cervical AI algorithm is intended as an aid and decision-support tool, meaning human pathologist review remains critical. If there is any uncertainty in the digital review, direct examination of the glass slide by light microscopy must be performed. Pathologists must interpret digital images in conjunction with patient history, risk factors, and professional guidelines, and review the entire AI-generated gallery to minimize interpretive errors and mitigate potential automation bias.
The Geniusu2122 Cervical AI algorithm demonstrates improved sensitivity compared to traditional manual and image-guided review methods. It has shown a reported 28.0% reduction in false-negative rates for high-grade squamous intraepithelial lesions (HSILs) and offers increased detection of endocervical components and infectious organisms. Clinical validation studies have indicated improved diagnostic accuracy and reduced screening time with the AI-based digital evaluation.
The system incorporates a Geniusu2122 Image Management Server (IMS) that functions as the central data manager, responsible for secure storage and retrieval of slide image data and patient information. It utilizes an HTTPS server for interfacing and is designed to comply with healthcare data privacy regulations like HIPAA, ensuring confidentiality and integrity throughout the diagnostic process.
The cost structure for implementing the system typically involves an initial capital investment for the hardware and software components, along with potential recurring service or licensing fees. Importantly, the use of the Geniusu2122 Digital Diagnostics System does not change CPT coding and does not add cost for patients. Reimbursement for AI-assisted diagnostics is an evolving area, and specific coverage may vary by payer and region.

Related Tools

AI-Powered OBGYN & Gynecologic Chats
Doctronic
Clinical Decision Support & Reference
Doctronic's AI-Powered OBGYN & Gynecologic Chats provide fast, personalized guidance for menstrual health, pregnancy support, UTIs, and reproductive care using advanced AI.
Free chat, $39/video visit with a doctor, prescription renewals starting at $0.
Mirvie
Mirvie
Clinical Decision Support & Reference
Mirvie is shaping the future of pregnancy health by providing women, expecting parents, and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.
Babyscripts
Babyscripts
OB/GYN AI
Babyscripts helps care teams close the loop on maternal risk with configurable screening and monitoring tools that connect patients to the right care pathway for timely, coordinated follow-up.
Subscription-based model
Butterfly Gestational Age Tool
Butterfly Network
OB/GYN AI
The Butterfly Gestational Age Tool is an AI-powered ultrasound feature designed to assist in rapid and accurate gestational age estimation.
Starts at $2,699 for the handheld probe, plus a required membership subscription.
AI-powered Postpartum Depression Risk Prediction Model (integrated into Epic)
NewYork-Presbyterian and Weill Cornell Medicine
Clinical Decision Support & Reference
An AI-powered risk prediction model developed at NewYork-Presbyterian and Weill Cornell Medicine uses data in electronic health records to identify pregnant patients at risk for postpartum depression (PPD), enabling preventive care. Integrated directly into Epic, the tool flags medium- to high-risk patients within physicians' workflows and provides risk scores, contributing factors, and suggested interventions to support clinical decision-making.
Natural Cycles (NC° Fertility Algorithm)
Natural Cycles
OB/GYN AI
Natural Cycles is an FDA-cleared birth control app with an AI-powered fertility algorithm that combines statistical modeling with machine learning to generate individualized fertility predictions. It's designed to help women prevent or plan pregnancies and offers support for various stages of their reproductive journey, from birth control to perimenopause. [4, 7, 18]
Subscription-based

See all OB/GYN AI tools →

More from Hologic

Genius AI Detection
Hologic
Oncology AI
Hologic's Genius AI Detection is a deep learning-based software that assists radiologists in the early detection of breast cancer by identifying suspicious lesions in breast tomosynthesis images, reducing false positives, and optimizing workflow.
Contact for pricing
Genius AI Detection 2.0 with CC-MLO Correlation
Hologic
Oncology AI
Hologic Genius AI Detection 2.0 with CC-MLO Correlation is an FDA-cleared AI-powered software for digital breast tomosynthesis, designed to enhance breast cancer detection by identifying suspicious lesions and correlating findings across CC and MLO views, improving diagnostic accuracy and workflow efficiency for radiologists.
Contact vendor
M1000 IMAGECHECKER
Hologic
Oncology AI
Hologic's M1000 ImageChecker is an FDA-cleared computer-aided detection (CAD) system that assists radiologists in identifying suspicious areas on mammograms, such as microcalcifications and masses, to aid in the early detection of breast cancer.
Not available publicly for this legacy product; contact vendor.
Quantra
HOLOGIC
Oncology AI
Hologic Quantra 2.2 is an FDA-cleared AI-powered software that automates and standardizes breast density assessment from mammography images, categorizing breast tissue according to BI-RADS guidelines to aid radiologists.
Contact vendor for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.